{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:24:31Z","timestamp":1770481471496,"version":"3.49.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"sanofi-aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.ejca.2012.07.007","type":"journal-article","created":{"date-parts":[[2012,8,24]],"date-time":"2012-08-24T05:15:51Z","timestamp":1345785351000},"page":"17-24","source":"Crossref","is-referenced-by-count":28,"title":["Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours"],"prefix":"10.1016","volume":"49","author":[{"given":"Eric","family":"Van Cutsem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Khayat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Verslype","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Billemont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Tejpar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Meric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Soussan-Lazard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Assadourian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvaine","family":"Cartot-Cotton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Rixe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2012.07.007_b0005","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/ATVBAHA.108.179663","article-title":"Vascular endothelial growth factor","volume":"29","author":"Ferrara","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ejca.2012.07.007_b0010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/157489207779561426","article-title":"Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy","volume":"2","author":"Veeravagu","year":"2007","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"10.1016\/j.ejca.2012.07.007_b0015","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2012.07.007_b0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.07.007_b0025","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/1078-0432.CCR-06-1989","article-title":"Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions","volume":"13","author":"Rini","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2012.07.007_b0030","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2012.07.007_b0035","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1158\/1078-0432.CCR-06-2553","article-title":"Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model","volume":"13","author":"Verheul","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2012.07.007_b0040","first-page":"5721","article-title":"Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model","volume":"9","author":"Byrne","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2012.07.007_b0045","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1158\/1078-0432.CCR-03-0820","article-title":"Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines","volume":"10","author":"Fukasawa","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2012.07.007_b0050","doi-asserted-by":"crossref","first-page":"7785","DOI":"10.1073\/pnas.1432908100","article-title":"Regression of established tumors and metastases by potent vascular endothelial growth factor blockade","volume":"100","author":"Huang","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2012.07.007_b0055","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JCO.2009.22.9237","article-title":"Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors","volume":"28","author":"Lockhart","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.07.007_b0060","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/1078-0432.CCR-09-2103","article-title":"Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors","volume":"16","author":"Tew","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2012.07.007_b0065","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/ndt\/gfl565","article-title":"Thrombotic microangiopathy and anti-VEGF agents","volume":"22","author":"Izzedine","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejca.2012.07.007_b0070","doi-asserted-by":"crossref","first-page":"18363","DOI":"10.1073\/pnas.0708865104","article-title":"Inaugural Article: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade","volume":"104","author":"Rudge","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2012.07.007_b0095","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1073\/pnas.081615298","article-title":"Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer","volume":"98","author":"Kuo","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2012.07.007_b0100","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912005680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912005680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T05:01:37Z","timestamp":1588827697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804912005680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0959804912005680"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2012.07.007","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}